Human Leukocyte Antigen (HLA) Based Platform Market

Global Human Leukocyte Antigen (HLA) Based Platform Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2024-2030: The factors such as the rising occurrence of chronic diseases, growing need for organ transplants, and technological development are escalating the demand for Global Human Leukocyte Antigen (HLA) Based Platform Market.

Global Human Leukocyte Antigen (HLA) Based Platform Market is valued at USD 1.2 Billion in 2024, and it is expected to reach USD 1.9 Billion by 2030 with a CAGR of 6.2% over the forecast period.

Scope:

Human leukocyte antigens (HLA) are a vital group of genes located within the major histocompatibility complexes (MHC). These genes play a key role in coding proteins that are crucial for the immune system, helping the body recognize and fend off harmful invaders. While HLA genes are essential for boosting immunity and preventing illness, they can occasionally have unintended negative effects. HLA molecules are expressed on the surface of cells, where they act as sentinels, orchestrating immune responses and maintaining the body's defense systems. HLA present specific antigens to T lymphocytes and lead to immune response to inflammatory as well as malignant diseases. Generally, HLA based platform is used for cord blood unit matching during organ transplantation. These platforms assist in determining whether the blood types of the donor and recipient are compatible.

HLA typing was first identified in the mid-20th century and has since become crucial in various fields, particularly immunogenetics and organ transplantation. The HLA Typing was initially used to ensure compatibility for transplants. However, advancements in polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies brought a drastic change in accuracy and speed of HLA testing. These developments helped HLA typing to explore its applications including diagnostics and drug research, in addition to transplantation.

As the number of cancer cases reported increases, there is focusing more on cancer immunotherapies and the HLA based platform’s scope is widening in immunotherapy and vaccines development. HLA typing is useful in determining patient centered immune responses necessary for developing targeted therapies. In addition, HLA data analysis has been enhanced through the implementation of machine learning and bioinformatics approaches. This leads to increased specific predictors such as treatment response and even disease risk. However, the market for precision healthcare and therapeutic innovation on this platform is expected to grow in the future with numerous applications.

Revenue Generation Model:

Revenue generation model involves the sale of components related to HLA based platforms. It involves kits that are used for HLA typing. Companies generate their revenue through the sale of these kits such as HLA-B typing kit, HLA-C typing kit reagents, and software required for HLA typing. Some companies generate revenue through the provision of services related to HLA typing.

Supply Chain Analysis:

Supply chain analysis involves processes right from raw material to delivery of products. The components of the supply chain involve distributors, manufacturers, and raw material suppliers. Manufacturers source high-quality raw materials from trusted vendors to create specialized kits. Once produced, these kits are efficiently distributed through a network of distributors, ensuring they reach the hands of end users swiftly and reliably. This streamlined process guarantees that the right products are available where and when they’re needed most.

Value Chain Analysis:

Value chain analysis involves analysis of value adding elements at each step of supply chain. It comprises of production, marketing, distribution, and research & development. Firstly, researchers work on the HLA based systems for their efficacy studies and after getting approval that product further passes through manufacturing, marketing, distribution and reaches end users.

Key Market Players:

Thermo Fisher Scientific, Qiagen N.V., CareDx, Omixon Ltd., Bio-Rad Laboratories, GenDx, PacBio, Roche Diagnostics, BD Biosciences, Immucor, Creative Biolabs, VH Bio, Sciencell Research Laboratories, Anatolia Geneworks, Discovery Life Sciences, CD Genomics, CapitalBio Technology, Bag Health Care, Illumina, Olerup, TBG Diagnostics, Fujirebio, Histogenetics, Abbott, Biofortuna. These are some of the major key players providing kits as well as services associated with Human Leukocyte Antigen (HLA).

Market Drivers:

Intensifying prevalence of chronic diseases with organ transplantation is fueling the Human Leukocyte Antigen (HLA) Based Platform Market:

HLA typing is the preferred method for organ transplantation. During organ transplants or blood transfusions, it is necessary to match the cord blood units. The HLA-based platform helps determine whether there is a match. Essentially, HLA are markers present on various cells. HLA typing helps detect whether the cord blood units of the donor and recipient are compatible. For certain diseases, organ transplantation or blood transfusion is critical. Diseases such as cancer and autoimmune disorders require HLA-based platforms for successful transplantation.

For instance, according to the CDC, 129 million Americans suffer from at least one severe chronic illness, including diabetes, cancer, heart disease, obesity, or hypertension. Such high numbers indicate the need for organ transplantation in severe cases. Moreover, in 2023, according to Canadian Institute for Health Information, a total of 3,428 organ transplants were performed in Canada. So, while doing transplantation there is necessity of HLA based platforms to match the cord blood unit. This increasing prevalence of chronic diseases and increasing need for organ transplantation is acting as a fueling factor in the growth of Human Leukocyte Antigen (HLA) Based Platform Market.

Advancements in HLA based platforms with different types of applications are stimulating the market to penetrate in different ways:

HLA platforms are used in transplantation diagnosis. Technological advancements are revolutionizing HLA platform to be used for different diseases with different approaches. HLA is used for organ transplantation diagnosis where matching between donors and recipient is performed. But some ambiguities remain with respect to matching HLA typing. Additionally, rising some technological advancements such as Next Generation Sequencing (NGS). NGS provides thorough genomic characterization & delivers high-resolution typing results at more than 2 field levels. It helps to enhance accuracy through parallel sequencing.

Moreover, advancements in HLA research extend beyond diagnostics to transformative treatments. HLA molecules are now being harnessed in the treatment of diseases like cancer, playing a key role in cutting-edge immunotherapy. Certain HLA molecules, known for their ability to activate the immune system in patients with autoimmune disorders, are being strategically used to enhance therapeutic outcomes. This innovative platform targets multiple components of the innate immune system. For example, as of February 2024, HLA-G is emerging as a promising candidate in cancer therapy, showing immense potential in revolutionizing the way we approach treatment. HLA-G is a non-classical major MHC class I molecule enriched on various malignant cells which facilitates immunosuppressive cells. HLA-G stands out as crucial immune response that promises benefits for cancer patients.

Restraining Factor:

High Cost for Access to HLA Based Platforms is Restricting the Market to Grow:

HLA based platforms involve utilization of different types of reagents, instruments, and software. All these components are expensive and need high-cost asset investment along with capital investment. Also, the maintenance is required for the instruments being utilized for the whole process. So, when the service providers or the kit manufacturers sell their service or product, it ultimately costs high for the end users.

Furthermore, the launch of new technologies such as Next Generation Sequencing (NGS) requires significant investment and ultimately turns into high cost for service as well as product. In HLA type, single antigen costs US$ 34 to US$ 194. This range varies with antigen types and use it is being utilized for. Hence, such high cost somewhere restricts the consumers from utilizing these technologies. Countries from regions such as Middle East Africa cannot afford such high costs. So, it is one of the reasons which restrict the growth of the market.

Opportunity Factor:

Artificial intelligence in HLA:

Artificial intelligence is the preferable platform being utilized across different sectors including biotechnology. It helps to predict some kind of results before experimentation. Likewise, some companies are doing research and development in AI based HLA techniques. This is going to be a huge advancement in HLA based platforms. It will help to target the specific cells while utilizing them for treatment of diseases, to predict the presence of proteins over specific cells while transplantation diagnosis. Such advancement will revolutionize HLA based platforms. For instance, in March 2024, Arizona State University scientists developed an AI based learning tool named HLA Inception. These groundbreaking advancements are fostering a dynamic and opportunistic environment for the HLA-based platform market. As innovative therapies and diagnostic solutions continue to evolve, the potential for growth and development in this sector is vast, paving the way for new breakthroughs and enhanced patient care.

Market Trends:

HLA Platform is emerging with innovative applications in cancer:

HLA platform is applicable in diagnosis as well as treatment of disease. It has been used mostly for diagnosis of disease. Some of the diseases for which HLA platform is applicable include cancer, diabetes, cardiovascular disorders etc. But specifically with a particular disease, HLA platform is becoming applicable. For example, one of the research projects conducted by Cristina Ferrone in June 2024, revealed potential of HLA platform as immunotherapy for pancreatic cancer. The study explained that patients having high levels of HLA class I expressed on the pancreatic cancer, it suggests that their body is better to fight cancer. This type of study is opening doors for upcoming research and advancements in HLA based platform market.

Customer Trends:

Customers are always in search of a precise and accurate diagnostic tool as well as treatment option. Customers do not have access to all the technologies as some of them are being utilized for research purposes only. So, customers are demanding the utilization of technologies for more accuracy during transplantation of organs as well as cancer treatment. This approach is creating an aura for bringing the technologies for diagnosis as well as treatment use.

Market Competition Nature:

Collaborations: In November 2023, GenDx and OSE Immunotherapeutics collaborated to develop CDx test. NGSengine software and the NGSgo HLA-A typing kit are used as a CDx for an epitope-based cancer vaccine. Under this collaboration, GenDx developed and validated a companion diagnostic test to identify patients with HLA-A*02 genotype. This collaboration helped GenDx to support growing demand of customers globally for innovative transplant diagnostic products. This ultimately turned into revenue growth as the demand surged at global level.

Merger & Acquisition: Several companies looking to enter the AI-powered enzyme design market face challenges with foundational technology. To overcome this hurdle and accelerate their entry, many opt for strategic mergers and acquisitions, leveraging partnerships to gain access to cutting-edge innovations and stay competitive. For instance, in 2024, Eurobio Scientific agreed to acquire HLA diagnostic expert company GenDx. The agreement was signed for US$ 137.1 million. GenDx specializes in molecular diagnostics of transplants by HLA typing. This acquisition allowed Eurobio Scientific to complete its portfolio with 100% proprietary products in the field of HLA.

Geography Analysis:

With the Highest Prevalence and Advanced Healthcare Infrastructure North America Dominates the HLA Based Platform Market:

HLA based platforms prominently deal with chronic diseases for transplantation related diagnosis as well as immunotherapy. It primarily focuses on cancer and autoimmune diseases. North America has the highest rate of chronic diseases in the world. For example, according to Centers for Disease Control & Prevention (CDC), 90% of the annual health spending of US$ 4.5 trillion is directed towards individuals with chronic and mental health conditions. This much expenditure is there in the United States for people with chronic diseases. This number indicates how many patients are suffering from chronic diseases in the USA where the expenditure acquires 90% of total healthcare expenditure. The number indicates the need as well as demand for immunotherapy and organ transplantation in the USA. For both things, HLA based techniques are utilized dominantly. So, ultimately, these factors are creating growth opportunities in North America for HLA based platform market. So, by considering prevalence North America dominates the HLA based platform market.

Increasing investments in HLA based platforms is making Europe the second dominating region:

As HLA is a technique utilized for different purposes such as diagnosis as well as treatment, it requires different kinds of instruments, software and reagents. Accordingly, the cost of these elements varies with their applications. So, there is a requirement for investments to be made in such technologies. Being a high-cost investment in technology, some collaborations work to invest in technology. For instance, in September 2024, ImmunOs therapeutics raised US$ 11 Mn, DeepDrive bags funded US$ 32 Mn for developing immune system-modulating HLA-based technology platform for the treatment of cancer and autoimmune diseases. Such a high investment helps to carry the market towards growth in that region. With these investments, Europe stands second in the HLA based platform market.

What are the Key Benefits of Global Human Leukocyte Antigen (HLA) Based Platform Market Report to You?

• Global Human Leukocyte Antigen (HLA) Based Platform Market report covers in-depth historical and forecast analysis.
• Global Human Leukocyte Antigen (HLA) Based Platform Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Human Leukocyte Antigen (HLA) Based Platform Market report helps to identify opportunities in the marketplace.
• Global Human Leukocyte Antigen (HLA) Based Platform Market report covers extensive analysis of emerging trends and competitive landscape.

Global Human Leukocyte Antigen (HLA) Based Platform Market Segmentation:

By Offering Type:

• Instruments
  • Sequencing Instruments
  • Flow Cytometers
  • PCR Machines
• Reagents and Consumables
  • Sequencing Reagents
  • Antibodies
  • Assay Kits
• Software
  • HLA Typing Software
  • HLA Data Analysis Software

By Technology

• Molecular Assays
  • PCR Based HLA Typing
  • Next Generation Sequencing (NGS)
  • Sanger Sequencing
• Serological Assays

By Applications:

• Disease Diagnosis
  • Autoimmune Disease Diagnosis
  • Infectious Disease Diagnosis
• Transplantation
  • Organ Transplantation
  • Bone Marrow Transplantation
• Drug Discovery and Development
  • Immunotherapy
  • Personalized Medicine
• Research Applications
  • Genomics and Proteomics Research
  • Population Genetics

By End Users

• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Hospitals & Transplant Centers
• Research Institutes
• Others

By Regional & Country Level:

• Europe
  • K.
  • France
  • Germany
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
• North America
  • S.
  • Canada
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa